Search results for "interventio"

showing 10 items of 3167 documents

Prevalence and characteristics of coronary artery disease in a population with suspected ischaemic heart disease using CT coronary angiography: corre…

2008

Purpose. This study was undertaken to describe the correlation between the distribution of coronary artery disease (CAD) in a symptomatic population with suspected ischaemic heart disease, cardiovascular risk factors (RF) and clinical presentation. Materials and methods. We studied 163 patients (mean age 65.5 years; 101 men and 62 women) referred for multidetector computed tomography coronary angiography (MDCT-CA) to rule out CAD. The patients had no prior history of revascularisation or myocardial infarction. We analysed how the characteristics of CAD (severity and type of plaque) can change with the increase in RF and how they are related to different clinical presentations. Results. Pati…

Malemedicine.medical_specialtyCT coronary angiographyPopulationMyocardial IschemiaCoronary Artery DiseaseCoronary AngiographySensitivity and SpecificityCoronary artery diseasePredictive Value of TestsInternal medicineEpidemiologyPrevalencemedicineHumansrisk factorsRadiology Nuclear Medicine and imagingMyocardial infarctioneducationAgedNetherlandsNeuroradiologyeducation.field_of_studyFramingham Risk Scoremedicine.diagnostic_testbusiness.industryReproducibility of Resultssuspected coronary artery diseaseInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseCT coronary angiography Risk factors Epidemiology Suspected coronary artery diseaseCardiologyFemaleepidemiologyPresentation (obstetrics)Tomography X-Ray ComputedSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessRadiologia Medica
researchProduct

Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to p…

2019

To determine whether the LI-RADS imaging features of primary liver carcinomas (PLCs) other than hepatocellular carcinoma (non-HCC PLCs) differ between patients considered high risk (RF+) versus not high risk (RF−) for HCC and to compare rates of miscategorization as probable or definite HCC between the RF+ and RF− populations. This retrospective study included all pathology-proven non-HCC PLCs imaged with liver-protocol CT or MRI from 2007 to 2017 at two liver transplant centers. Patients were defined per LI-RADS v2018 criteria as RF+ or RF−. Two independent, blinded readers (R1, R2) categorized 265 lesions using LI-RADS v2018. Logistic regression was utilized to assess for differences in i…

Malemedicine.medical_specialtyCarcinoma HepatocellularContrast MediaTarget populationLogistic regressionGastroenterologyLiver neoplasm030218 nuclear medicine & medical imagingLiver cirrhosiDiagnosis DifferentialCholangiocarcinoma03 medical and health sciences0302 clinical medicinehepatocellularRisk FactorsInternal medicineBile duct neoplasmHumansMedicineSingle-Blind MethodRadiology Nuclear Medicine and imagingAgedRetrospective StudiesNeuroradiologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCarcinomaRetrospective cohort studyInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesExact testLogistic Models030220 oncology & carcinogenesisHepatocellular carcinomaFemaleRadiologyTomography X-Ray ComputedbusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaArterial phase
researchProduct

3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: prelimi…

2014

Objective: To investigate diagnostic performance of 3D contrast-enhanced ultrasound (CEUS) compared with 2D CEUS in the assessment of therapeutic response of hepatocellular carcinoma (HCC) treated with locoregional therapies (LRT). Materials and methods: Twenty-three consecutive patients (13 men and 10 women; mean age 65.5 years) with 23 HCCs (size range 1.2–7.2 cm; mean size 2.9 ± 1.4 cm) treated by means of radiofrequency ablation (RFA n = 9), transarterial chemoembolization (TACE n = 8), combined RFA and TACE (n = 3), percutaneous alcoholization (n = 2), and wedge resection (n = 1) underwent 2D and 3D CEUS 1 month (30 ± 2 days) after treatment. Magnetic resonance (n = 17) and computed to…

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaRadiofrequency ablationContrast-enhanced 3D ultrasoundSulfur HexafluorideContrast MediaIopamidollaw.inventionImaging Three-DimensionallawImage Interpretation Computer-AssistedCarcinomamedicineHumansRadiology Nuclear Medicine and imagingPhospholipidsUltrasonography InterventionalAgedNeuroradiologyAged 80 and overmedicine.diagnostic_testbusiness.industryMedicine (all)Liver NeoplasmsUltrasoundInterventional radiologyMagnetic resonance imagingGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingIopamidolPhospholipidContrast agentTreatment OutcomeLiverLiver NeoplasmHepatocellular carcinomaFemaleRadiologyTomography X-Ray ComputedbusinessHumanmedicine.drugLa radiologia medica
researchProduct

Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound

2007

Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-sca…

Malemedicine.medical_specialtyCarcinoma HepatocellularPercutaneousRadiofrequency ablationUrologymedicine.medical_treatmentSulfur HexafluorideContrast MediaCatheter ablationSensitivity and Specificitylaw.inventionImaging Three-DimensionallawHumansMedicineRadiology Nuclear Medicine and imagingStage (cooking)PhospholipidsUltrasonography InterventionalAgedAged 80 and overRadiological and Ultrasound Technologybusiness.industryLiver NeoplasmsUltrasoundGastroenterologyGeneral MedicineRadiofrequency ablationcontrast-enhanced ultrasound hepatocellular carcinomamedicine.diseaseTreatment OutcomeHepatocellular carcinomaCatheter AblationDisease ProgressionMicrobubblesFemaleRadiologybusinessContrast-enhanced ultrasoundAbdominal Imaging
researchProduct

Incidence of new foci of hepatocellular carcinoma after radiofrequency ablation: role of multidetector CT

2012

Purpose. The authors sought to assess the incidence of new foci of hepatocellular carcinoma (HCC) using multidetector computed tomography (MDCT) in patients treated with radiofrequency ablation (RFA). Materials and methods. Two readers retrospectively reviewed by consensus the follow-up MDCT studies of 125 patients (88 men and 37 women; mean age 68 years) with 141 HCCs (size 1–5.2 cm; mean 2.2 cm) treated with RFA. MDCT follow-up was performed at 1 and 3 months and every 6–12 months thereafter. Reviewers assessed: (1) the presence of new HCC foci in the same liver segment or in a different segment; (2) complete or incomplete tumor ablation; (3) tumour progression. Results. A total of 113 ne…

Malemedicine.medical_specialtyCarcinoma HepatocellularRadiofrequency ablationMultidetector ctSettore MED/01 - Statistica Medicalaw.inventionLiver neoplasmslawMultidetector Computed TomographymedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesNeuroradiologyChi-Square Distributionmedicine.diagnostic_testbusiness.industryIncidenceIncidence (epidemiology)Radiofrequency ablation (RFA)UltrasoundInterventional radiologyGeneral MedicineMiddle AgedHCCSmedicine.diseasedigestive system diseasesTreatment OutcomeLiverHepatocellular carcinomaCatheter AblationDisease ProgressionRadiofrequency ablation (RFA); Liver; CT; Liver neoplasmsFemaleRadiologyNeoplasm Recurrence LocalSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessFollow-Up StudiesCTLa radiologia medica
researchProduct

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

2020

Cardiopulmonary resuscitation after cardiac arrest, independent of its origin, is a regularly encountered medical emergency in hospitals as well as preclinical settings. Prospective randomized trials in human subjects are difficult to design and ethically ambiguous, which results in a lack of evidence-based therapies. The model presented in this report represents one of the most common causes of cardiac arrests, ventricular fibrillation, in a standardized setting in a large animal model. This allows for reproducible observations and various therapeutic interventions under clinically accurate conditions, hence facilitating the generation of better evidence and eventually the potential for im…

Malemedicine.medical_specialtyCardiac outputResuscitationSwineGeneral Chemical Engineeringmedicine.medical_treatmentPsychological interventionMEDLINEAdvanced Cardiac Life SupportDecarboxylationGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineAnimals030212 general & internal medicineCardiopulmonary resuscitationCardiac OutputIntensive care medicineGeneral Immunology and Microbiologybusiness.industryGeneral NeuroscienceAdvanced cardiac life support030208 emergency & critical care medicinemedicine.diseaseCardiopulmonary ResuscitationOxygenDisease Models AnimalVentricular FibrillationVentricular fibrillationbusinessJournal of Visualized Experiments
researchProduct

Lipid Profile Results after Cardiovascular Prevention Programme: Euroaction Model in Spain

2020

Background: Cardiovascular prevention and rehabilitation programmes (CVPRP) are an established model of care designed to improve risk factor management. They have been successfully implemented in a variety of settings, in patients with coronary heart disease (CHD). Objective: To assess the long term impact of a nurse-coordinated, multidisciplinary, CVPRP in patients with CHD in the reduction of lipid profile and medication prescription in clinical practice. Methods: The study used an analytical, experimental, population based, prospective and longitudinal design. In Spain, the study was conducted in the Valencian Community, including two randomized hospitals. Coronary patients were prospec…

Malemedicine.medical_specialtyCardiotonic AgentsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentNurse's RoleMedication prescriptionCardiovascular preventionIntervention (counseling)HumansImmunology and AllergyMedicineLongitudinal StudiesProspective StudiesMedical prescriptionHealth policyAgedRehabilitationmedicine.diagnostic_testbusiness.industryMiddle AgedLipidsCoronary heart diseaseEuropePrimary PreventionCardiovascular DiseasesSpainEmergency medicineFemaleDiet HealthyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLipid profileRisk Reduction BehaviorEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: Pleiotropic evidence from plasma mRNA analyses

2013

Objective: Statin pleiotropy is still an evolving concept, and the lack of clarity on this subject is due at least in part to the lack of a definitive biomarker for statin pleiotropy. Using plasma mRNA analysis as a novel research tool for the non-invasive in vivo assessment of gene expression in vascular beds, we hypothesised that atorvastatin lowers the plasmamRNA level from statin pleiotropy-target genes, and the reduction is independent of the reduction of low-density lipoprotein cholesterol (LDL-C). Design and methods: Forty-four patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). Plasma chemokine (C-C motif) ligand 2 (CCL2) and intercellular adhesion molec…

Malemedicine.medical_specialtyChemokineStatinmedicine.drug_classAtorvastatinClinical BiochemistryGene ExpressionDrug Administration ScheduleIn vivoInternal medicineGene expressionAtorvastatinmedicineHumansPyrrolesAngina StableRNA MessengerSerum amyloid AChemokine CCL2AgedbiologyAnticholesteremic AgentsAtorvastatin CCL2 ICAM1 Interventional trial mRNA in plasma Pleiotropic effectsC-reactive proteinCholesterol LDLGeneral MedicineMiddle AgedIntercellular Adhesion Molecule-1EndocrinologyHeptanoic AcidsHMG-CoA reductasebiology.proteinFemalelipids (amino acids peptides and proteins)medicine.drugClinical Biochemistry
researchProduct

Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.

2021

Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention has developed into its own subspecialty of interventional cardiology. Dedicated terminology, techniques, devices, courses, and training programs have enabled progressive advancements. However, only a few randomized trials have been performed to evaluate the safety and efficacy of CTO percutaneous coronary intervention. Moreover, several published observational studies have shown conflicting data. Part of the paucity of clinical data stems from the fact that prior studies have been suboptimally designed and performed. The absence of standardized end points and the discrepancy in definitions also prevent…

Malemedicine.medical_specialtyClinical trial protocols as topicmedicine.medical_treatmentPsychological intervention030204 cardiovascular system & hematologySubspecialtylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawPhysiology (medical)MedicineHumansMedical physics030212 general & internal medicineCoronary VesselClinical Trials as TopicInterventional cardiologybusiness.industryClinical study designPercutaneous coronary interventionCoronary VesselsCoronary OcclusionCoronary occlusionEndpoint determination:Myocardial revascularizationObservational studyFemaleCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department

2020

Objectives To evaluate clinical and financial impact of pharmacist interventions in an ambulatory adult hematology–oncology department. Methods All cancer patients receiving a first injectable immuno- and/or chemotherapy regimen were included in this prospective study over a one-year period. The clinical impact of pharmacist interventions made by two clinical pharmacists was rated using the Clinical Economic and Organizational tool. Financial impact was calculated through cost savings and cost avoidance. Main results: Five hundred and fifty-eight patients were included. A total of 1970 pharmacist interventions were performed corresponding to a mean number of 3.5 pharmacist interventions/pat…

Malemedicine.medical_specialtyCost-Benefit AnalysiseducationPharmacistsAmbulatory Care Facilities03 medical and health sciences0302 clinical medicineCost SavingsNeoplasmsHumansMedicinePharmacology (medical)Prospective Studies030212 general & internal medicineEconomic impact analysishealth care economics and organizationsPharmacist interventionAgedAged 80 and overPatient care teambusiness.industryFinancial impactCancerMiddle Agedmedicine.diseaseCost savingsOncology030220 oncology & carcinogenesisFamily medicineAmbulatoryFemalePharmacy Service HospitalbusinessHematology+OncologyJournal of Oncology Pharmacy Practice
researchProduct